Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast...
Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults...
Much has been written, including on this blog, about the rapidly expanding use of immunotherapy to treat an increasing...
In the fall issue, Cancer Today had the honor of highlighting two women whose cancer diagnoses led them to...
Pancreatic cancer is a deadly disease with a five-year survival rate of a mere 8.2 percent, according to statistics...
Cigarette smoking is the leading cause of death from lung cancer in the United States. That’s why November, Lung...
Last week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) for treating adults...
Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers,...
Paul Northcott, PhD, inaugural recipient of the AACR NextGen Grant for Transformative Cancer Research, has dedicated his research career...
Beginning this Friday, Philadelphia will host the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference,...
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a revolutionary new type of immunotherapy...